PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26548081-4	2015	In the present study, we explored the binding interactions of antidiabetic drugs i.e., sulfonylurea drugs (glimepiride, glipizide, glyburide) and rapid acting insulin secretagogues viz., nateglinide, repaglinide and rosiglitazone; and Pgp inhibitors i.e., Generation I (verapamil and tamoxifen), III (tetradrine and tariquidar), and natural inhibitors (fumagillin and piperine) in mouse Pgp model.	fumagillin	353-363	insulin	Homo sapiens	159-166
26548081-6	2015	These observations elucidate the role of fumagillin and piperine as potential natural compounds which could intervene in the efflux action of Pgp in extruding the antidiabetic drugs and may have implications for increasing efficacy of oral antidiabetic therapy.	fumagillin	41-51	phosphoglycolate phosphatase	Mus musculus	142-145
23480755-2	2012	Fumagillin, a specific MetAP2 inhibitor, suppresses CCA cell proliferation.	fumagillin	0-10	methionyl aminopeptidase 2	Homo sapiens	23-29
24568283-4	2014	Here, we report the identification and characterization of three oxygenases from the fumagillin biosynthetic pathway, including a multifunctional cytochrome P450 monooxygenase, a hydroxylating nonheme-iron-dependent dioxygenase, and an ABM family monooxygenase for oxidative cleavage of the polyketide moiety.	fumagillin	85-95	cytochrome P450 family 20 subfamily A member 1	Homo sapiens	146-175
23505365-7	2013	We sequenced the MetAP2 gene for apid Nosema species and determined that, although susceptibility to fumagillin differs among species, there are no apparent differences in fumagillin binding sites.	fumagillin	101-111	methionine aminopeptidase 2	Apis mellifera	17-23
23121865-7	2013	As a result, a 48-hr exposure to fumagillin significantly increased [Ca(2+)](i) (>=10 muM), enhanced ceramide abundance (100 muM), triggered annexin V binding (>=10 muM) and decreased forward scatter (>=10 muM).	fumagillin	33-43	latexin	Homo sapiens	89-92
23121865-7	2013	As a result, a 48-hr exposure to fumagillin significantly increased [Ca(2+)](i) (>=10 muM), enhanced ceramide abundance (100 muM), triggered annexin V binding (>=10 muM) and decreased forward scatter (>=10 muM).	fumagillin	33-43	latexin	Homo sapiens	128-131
23121865-7	2013	As a result, a 48-hr exposure to fumagillin significantly increased [Ca(2+)](i) (>=10 muM), enhanced ceramide abundance (100 muM), triggered annexin V binding (>=10 muM) and decreased forward scatter (>=10 muM).	fumagillin	33-43	latexin	Homo sapiens	128-131
23121865-7	2013	As a result, a 48-hr exposure to fumagillin significantly increased [Ca(2+)](i) (>=10 muM), enhanced ceramide abundance (100 muM), triggered annexin V binding (>=10 muM) and decreased forward scatter (>=10 muM).	fumagillin	33-43	latexin	Homo sapiens	128-131
23480758-2	2012	We reported previously suppressive effects of fumagillin, a MetAP2 inhibitor, on growth of CCA cell lines.	fumagillin	46-56	methionyl aminopeptidase 2	Homo sapiens	60-66
22229417-5	2012	Several fumagillin analogs, like CKD-732, TNP-470 and PPI-2458, were found to be potent selective inhibitors of MetAP-2 (proteolytic activity) and endothelial cell proliferation.	fumagillin	8-18	methionyl aminopeptidase 2	Homo sapiens	112-119
20094042-1	2010	The effect of fumagillin (a methionine aminopeptidase-type 2 (Met-AP2) inhibitor, with antiangiogenic properties) was investigated in murine models of diet-induced obesity.	fumagillin	14-24	methionine aminopeptidase 2	Mus musculus	62-69
22509410-0	2012	Early treatment with fumagillin, an inhibitor of methionine aminopeptidase-2, prevents Pulmonary Hypertension in monocrotaline-injured rats.	fumagillin	21-31	methionyl aminopeptidase 2	Rattus norvegicus	49-76
19563408-5	2009	The Fumagillin-treated mice had smaller tumor mass, fewer pulmonary metastases, and lower MVD-CD105 levels than control animals.	fumagillin	4-14	endoglin	Mus musculus	94-99
19961899-2	2010	METHODS: The effect of fumagillin (a methionine aminopeptidase-2 inhibitor) on adipocyte differentiation and de novo adipogenesis was investigated in murine model systems.	fumagillin	23-33	methionine aminopeptidase 2	Mus musculus	37-64
19648008-1	2009	Fumagillin, an irreversible inhibitor of MetAP2, has been shown to potently inhibit growth of malaria parasites in vitro.	fumagillin	0-10	methionine aminopeptidase 2	Mus musculus	41-47
16004378-6	2005	Fumagillin is an irreversible inhibitor of methionine aminopeptidase type 2 (MetAP2).	fumagillin	0-10	methionyl aminopeptidase 2	Homo sapiens	43-75
17446530-5	2007	Fumagillin, an irreversible inhibitor of the enzymatic activity of MetAP2, attenuated collagen deposition in the bleomycin model of acute lung injury in mice.	fumagillin	0-10	methionine aminopeptidase 2	Mus musculus	67-73
17450475-9	2007	Fumagillin, a MetAP2 specific inhibitor, significantly inhibited cell proliferation in dose dependent manner and the degree of growth inhibition was dependent on the amount of cellular enzyme.	fumagillin	0-10	methionyl aminopeptidase 2	Homo sapiens	14-20
16970390-3	2006	It is shown that, like fumagillin, fumarranol selectively inhibits MetAP2 and endothelial cell proliferation.	fumagillin	23-33	methionine aminopeptidase 2	Mus musculus	67-73
16267007-8	2005	In addition, we show that Nf1-deficient astrocytes overexpress MetAP2 in vitro and in vivo, and that treatment with the MetAP2 inhibitor fumagillin significantly reduces Nf1-/- astrocyte proliferation in vitro.	fumagillin	137-147	neurofibromin 1	Homo sapiens	26-29
16267007-8	2005	In addition, we show that Nf1-deficient astrocytes overexpress MetAP2 in vitro and in vivo, and that treatment with the MetAP2 inhibitor fumagillin significantly reduces Nf1-/- astrocyte proliferation in vitro.	fumagillin	137-147	methionyl aminopeptidase 2	Homo sapiens	63-69
16267007-8	2005	In addition, we show that Nf1-deficient astrocytes overexpress MetAP2 in vitro and in vivo, and that treatment with the MetAP2 inhibitor fumagillin significantly reduces Nf1-/- astrocyte proliferation in vitro.	fumagillin	137-147	methionyl aminopeptidase 2	Homo sapiens	120-126
16267007-8	2005	In addition, we show that Nf1-deficient astrocytes overexpress MetAP2 in vitro and in vivo, and that treatment with the MetAP2 inhibitor fumagillin significantly reduces Nf1-/- astrocyte proliferation in vitro.	fumagillin	137-147	neurofibromin 1	Homo sapiens	170-173
15962312-4	2005	The cellular levels of MetAP-2 enzyme were measured after MetAP-2 siRNA treatment and found to decrease over time from 4 to 96 h, while rapid and complete depletion of MetAP-2 enzyme activity was observed after 4 h treatment with two pharmacological inhibitors of MetAP-2, PPI-2458 and fumagillin.	fumagillin	286-296	methionyl aminopeptidase 2	Homo sapiens	23-30
15962312-5	2005	When HUVEC and A549 cells were treated simultaneously with MetAP-2 siRNA and PPI-2458, or fumagillin, which irreversibly inhibit MetAP-2 enzyme activity, no additive effect on maximum growth inhibition was observed.	fumagillin	90-100	methionyl aminopeptidase 2	Homo sapiens	129-136
16004378-6	2005	Fumagillin is an irreversible inhibitor of methionine aminopeptidase type 2 (MetAP2).	fumagillin	0-10	methionyl aminopeptidase 2	Homo sapiens	77-83
15474045-3	2004	MAP-2 protein displayed methionine aminopeptidase activity and was sensitive to inhibition by fumagillin.	fumagillin	94-104	Methionine aminopeptidase 2	Caenorhabditis elegans	0-5
15544353-0	2004	Treatment of cells with the angiogenic inhibitor fumagillin results in increased stability of eukaryotic initiation factor 2-associated glycoprotein, p67, and reduced phosphorylation of extracellular signal-regulated kinases.	fumagillin	49-59	methionine aminopeptidase 2	Mus musculus	150-153
15544353-1	2004	Fumagillin, an angiogenic inhibitor, binds to methionine aminopeptidase 2, which is the same as eukaryotic initiation factor 2-associated glycoprotein, p67.	fumagillin	0-10	methionine aminopeptidase 2	Mus musculus	46-73
15544353-1	2004	Fumagillin, an angiogenic inhibitor, binds to methionine aminopeptidase 2, which is the same as eukaryotic initiation factor 2-associated glycoprotein, p67.	fumagillin	0-10	methionine aminopeptidase 2	Mus musculus	152-155
9860943-10	1998	By using a fumagillin analog tagged with fluorescein, His-231 in MetAP2 was identified as the residue that is covalently modified by fumagillin.	fumagillin	11-21	methionyl aminopeptidase 2	Homo sapiens	65-71
14604668-3	2003	It was concluded that replacing the natural C4 of fumagillin with a benzyl oxime at C4 resulted in moderate loss of activity toward binding to MetAP2.	fumagillin	50-60	methionyl aminopeptidase 2	Homo sapiens	143-149
10636239-1	2000	New fumagillin analogues were designed through structure-based molecular modeling with a human methionine aminopeptidase-2.	fumagillin	4-14	methionyl aminopeptidase 2	Homo sapiens	95-122
10336480-11	1999	A variety of well characterized angiogenesis inhibitors (including angiostatin, fumagillin, 2-methoxy estradiol, transforming growth factor-beta, and thalidomide) effectively blocked VEGF-induced down-regulation of caveolin-1 as seen by immunoblotting and immunofluorescence microscopy.	fumagillin	80-90	vascular endothelial growth factor A	Homo sapiens	183-187
10336480-11	1999	A variety of well characterized angiogenesis inhibitors (including angiostatin, fumagillin, 2-methoxy estradiol, transforming growth factor-beta, and thalidomide) effectively blocked VEGF-induced down-regulation of caveolin-1 as seen by immunoblotting and immunofluorescence microscopy.	fumagillin	80-90	caveolin 1	Homo sapiens	215-225
9860943-10	1998	By using a fumagillin analog tagged with fluorescein, His-231 in MetAP2 was identified as the residue that is covalently modified by fumagillin.	fumagillin	133-143	methionyl aminopeptidase 2	Homo sapiens	65-71
9860943-12	1998	These results, in agreement with a recent structural study, suggest that fumagillin and ovalicin inhibit MetAP2 by irreversible blockage of the active site.	fumagillin	73-83	methionyl aminopeptidase 2	Homo sapiens	105-111
9224570-10	1997	A series of analogs of fumagillin and ovalicin were synthesized and their potency for inhibition of endothelial cell proliferation and inhibition of methionine aminopeptidase activity was determined.	fumagillin	23-33	carboxypeptidase Q	Homo sapiens	160-174
34913067-4	2022	Fumagillin and TNP-470, angiogenesis inhibitors that target MetAP2, significantly suppressed VM in various human cancer cell lines.	fumagillin	0-10	methionyl aminopeptidase 2	Homo sapiens	60-66
34913067-7	2022	Collectively, our results demonstrate that MetAP2 is critical for VM in human cancer cells and suggest fumagillin and TNP-470 as potent VM-suppressing agents.	fumagillin	103-113	methionyl aminopeptidase 2	Homo sapiens	43-49
34804032-9	2021	The negative impact of fumagillin and clothianidin on honey bee health was indicated by the lower expression of argonaute-2, dicer-like, abaecin, and hymenoptaecin, and vitellogenin.	fumagillin	23-33	protein argonaute-2	Apis mellifera	112-123
34804032-9	2021	The negative impact of fumagillin and clothianidin on honey bee health was indicated by the lower expression of argonaute-2, dicer-like, abaecin, and hymenoptaecin, and vitellogenin.	fumagillin	23-33	vitellogenin	Apis mellifera	169-181
33846894-5	2022	In search for potential reversible inhibitors, we built structure-based pharmacophore models using the crystal structure of MetAP2 complexed with fumagillin (PDB ID: 1BOA).	fumagillin	146-156	methionyl aminopeptidase 2	Homo sapiens	124-130
34572376-11	2021	Furthermore, fumagillin decreased TNF-alpha and IL-6 amounts and increased IL-10 levels at POD 7 and 14, but not IL-1beta concentrations.	fumagillin	13-23	tumor necrosis factor	Rattus norvegicus	34-43
34572376-11	2021	Furthermore, fumagillin decreased TNF-alpha and IL-6 amounts and increased IL-10 levels at POD 7 and 14, but not IL-1beta concentrations.	fumagillin	13-23	interleukin 6	Rattus norvegicus	48-52
34572376-11	2021	Furthermore, fumagillin decreased TNF-alpha and IL-6 amounts and increased IL-10 levels at POD 7 and 14, but not IL-1beta concentrations.	fumagillin	13-23	interleukin 10	Rattus norvegicus	75-80
31990576-1	2020	We examined the methionine aminopeptidase 2 inhibitor fumagillin in dogs consuming a high-fat and -fructose diet (HFFD).	fumagillin	54-64	methionyl aminopeptidase 2	Canis lupus familiaris	16-43
31990576-10	2020	Fumagillin improved glucose tolerance and NHGU in HFFD dogs, suggesting methionine aminopeptidase 2 (MetAP2) inhibitors have the potential for improving glycemic control in prediabetes and diabetes.	fumagillin	0-10	methionyl aminopeptidase 2	Canis lupus familiaris	72-99
31990576-10	2020	Fumagillin improved glucose tolerance and NHGU in HFFD dogs, suggesting methionine aminopeptidase 2 (MetAP2) inhibitors have the potential for improving glycemic control in prediabetes and diabetes.	fumagillin	0-10	methionyl aminopeptidase 2	Canis lupus familiaris	101-107
32252002-4	2020	Clinical studies show that the natural product fumagillin, and its analogs are potential inhibitors of MetAP2.	fumagillin	47-57	methionyl aminopeptidase 2	Homo sapiens	103-109
32252002-11	2020	Taken together, these uninherited-fumagillin compounds may serve as new class of inhibitors or provide scaffolds for further optimization towards the design of more potent MetAP2 inhibitors -development of such inhibitors would be essential strategy against various cancer types.	fumagillin	34-44	methionyl aminopeptidase 2	Homo sapiens	172-178
29515039-2	2018	Fumagillin, an inhibitor of methionine aminopeptidase-2, causes weight loss by reducing food intake, but with effects on weight that are superior to pair-feeding.	fumagillin	0-10	methionyl aminopeptidase 2	Rattus norvegicus	28-55